Evidence map›Paper›PMID 32546164›Full record

ArticleVirology journal2020

Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan.

Guan-Yu Lin, Yi-Le Wu, Cheng-Si Wang, Chia-Yun Ko, Chien-Hung Chen, Pei-Jer Chen, Po-Hsin Peng, Chao-Wei Hsu

Open access · goldAbstract readComparative Study
In one paragraph

Article in Virology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. [Research progress on the detection method of hepatitis D].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
  11. Digital Droplet PCR for Detection and Quantitation of Hepatitis Delta Virus.Clinical and translational gastroenterology · 2022
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Guan-Yu LinGeneral Biologicals Corporation, Hsinchu, 30076, Taiwan.
Yi-Le WuGeneral Biologicals Corporation, Hsinchu, 30076, Taiwan.
Cheng-Si WangGeneral Biologicals Corporation, Hsinchu, 30076, Taiwan.
Chia-Yun KoGeneral Biologicals Corporation, Hsinchu, 30076, Taiwan.
Chien-Hung ChenDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan.
Pei-Jer ChenHepatitis Research Center, National Taiwan University, Taipei, 10002, Taiwan.
Po-Hsin PengGeneral Biologicals Corporation, Hsinchu, 30076, Taiwan. jessica.peng@gbc.com.tw.
Chao-Wei HsuDepartment of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, 33305, Taiwan. hsu2406@adm.cgmh.org.tw.
Chang Gung University · TWKaohsiung Chang Gung Memorial Hospital · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis D virus (HDV) infection is a major global health issue around the world. There are approximately 15-20 million individuals infected with HDV worldwide. HDV infection usually causes increased mortality compared with infection with hepatitis B virus (HBV) alone. However, testing for the detection of HDV is not widely available in Taiwan. Therefore, the General Biologicals Corporation (GB) HDV Ab kit was developed for detecting anti-HDV antibodies.

methodsA total of 913 serum and 462 EDTA-treated plasma samples were obtained from HBsAg-positive individuals in three hospitals in Taiwan from June 2014 to November 2017. We used three commercially available ELISA kits, DiaPro HDV Ab, DiaSorin ETI-AB-DELTAK-2 and GB HDV Ab, which were utilized strictly according to the instructions of the manufacturers.

resultsA comparative study of the results from the GB HDV Ab kit and the other commercial ELISA kits (DiaPro and DiaSorin) was performed to determine their efficacy for anti-HDV detection. The results indicated that the sensitivity of the GB HDV Ab kit for serum and EDTA samples was 100% compared to that of the DiaPro and DiaSorin kits, whereas the specificity for serum and EDTA samples was 99.3 and 98.1%, respectively. In addition, the overall agreement of the results of the GB HDV Ab kit for the serum and EDTA samples was 99.3 and 98.3%, respectively. It is worth noting that the performance of the GB HDV Ab kit was not affected by interference from triglyceride, bilirubin, hemoglobin, or human anti-mouse antibody. The limit of detection of the GB HDV Ab kit is approximately 100-fold lower than that of the other two commercial kits.

conclusionsThe GB HDV Ab kit, which presented equivalent sensitivity and specificity compared to both certified anti-HDV kits, would be a suitable kit for HDV diagnosis in Taiwan.

Indexed as

Enzyme-Linked Immunosorbent AssayHepatitis AntibodiesHepatitis DHepatitis Delta VirusHumansLimit of DetectionReagent Kits, DiagnosticSensitivity and SpecificityTaiwanHepatitis AntibodiesReagent Kits, DiagnosticELISAHDVKit evaluationSensitivitySpecificity

Identifiers

PMID32546164
PMCPMC7298757
OpenAlexW3035063573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.